Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Signs For Takeda’s TAK-875 Suggest The GPR40 Agonist Could Take On Other Oral Antidiabetics

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.

You may also be interested in...



Alogliptin Rejection Dents Takeda’s Diabetes Franchise

Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.

Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials

Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel